Sodium‐glucose co‐transporter‐2 inhibitors and major adverse limb events: A trial‐level meta‐analysis including 51 713 individuals

Aim To analyse large‐scale cardiovascular outcome trials of sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors to evaluate whether there are safety concerns with respect to major adverse limb events overall or among various high‐risk subgroups of patients. Methods We performed a quantitative meta‐analysis of randomized, placebo‐controlled, cardiovascular outcome trials of SGLT‐2 inhibitors in patients with type 2 diabetes. We searched the...